Tamura Kohei, Takei Yuji, Matsubara Shigeki, Takahashi Suzuyo, Taneichi Akiyo, Takahashi Yoshifumi, Yoshiba Takahiro, Koyanagi Takahiro, Saga Yasushi, Fujiwara Hiroyuki
Department of Obstetrics and Gynecology, Jichi Medical University Hospital, Shimotsuke, Tochigi 329-0498, Japan.
Mol Clin Oncol. 2021 Dec;15(6):263. doi: 10.3892/mco.2021.2425. Epub 2021 Oct 25.
A previous study by our group reported that removing a larger number of lymph nodes in patients with stage I ovarian clear cell carcinoma (OCCC) improved progression-free survival (PFS). The present study investigated whether clinical conditions, particularly the number of removed lymph nodes, are independent predictors of progression for stage II or higher OCCC and whether the significance of the number of removed lymph nodes differs according to FIGO stage for OCCC. A total of 113 patients with OCCC who had undergone surgery between January 1993 and December 2015 were retrospectively enrolled and the clinicopathological data were obtained from their medical records. Among patients with stage II or higher OCCC, PFS of those with no residual tumor or no lymph node metastasis was significantly better than that of those with residual tumor (P=0.023) or lymph node metastasis (P=0.035). Multivariate analysis revealed that no residual tumor was the only independent predictor for improved PFS of patients with stage II or higher. Regarding the number of removed lymph nodes, it did not significantly affect the PFS of patients with stage II or higher OCCC, whereas it improved the PFS of those with stage I, being an independent predictor of progression of stage I OCCC. In summary, although the number of removed lymph nodes was an independent predictor of progression for stage I OCCC, it was not for stage II or higher OCCC. The prognostic significance of the number of removed lymph nodes in OCCC may differ depending on the FIGO stage.
我们团队之前的一项研究报告称,对于Ⅰ期卵巢透明细胞癌(OCCC)患者,切除更多数量的淋巴结可改善无进展生存期(PFS)。本研究调查了临床状况,尤其是切除淋巴结的数量,是否为Ⅱ期及更高分期OCCC进展的独立预测因素,以及切除淋巴结数量的意义是否因OCCC的国际妇产科联盟(FIGO)分期而异。回顾性纳入了1993年1月至2015年12月期间接受手术的113例OCCC患者,并从其病历中获取临床病理数据。在Ⅱ期及更高分期的OCCC患者中,无残留肿瘤或无淋巴结转移患者的PFS显著优于有残留肿瘤(P=0.023)或有淋巴结转移(P=0.035)的患者。多因素分析显示,无残留肿瘤是Ⅱ期及更高分期患者PFS改善的唯一独立预测因素。关于切除淋巴结的数量,它对Ⅱ期及更高分期OCCC患者的PFS没有显著影响,而对Ⅰ期患者的PFS有改善作用,是Ⅰ期OCCC进展的独立预测因素。总之,虽然切除淋巴结的数量是Ⅰ期OCCC进展的独立预测因素,但不是Ⅱ期及更高分期OCCC的独立预测因素。OCCC中切除淋巴结数量的预后意义可能因FIGO分期而异。